Authors: Hawley-Foss, N Mbisa, G Lum, JJ Pilon, AA Angel, JB Garber, G Badley, AD

Citation: N. Hawley-foss et al., Effect of cessation of highly active antiretroviral therapy during a discordant response: Implications for scheduled therapeutic interruptions, CLIN INF D, 33(3), 2001, pp. 344-348

Authors: Bernard, GR LaRosa, SP Laterre, PF Ely, EW Dhainaut, JF Fisher, CJ Lopez-Rodriguez, A Helterbrand, J Steingrub, J Garber, G Vincent, JL

Citation: Gr. Bernard et al., The efficacy and safety of recombinant human activated protein C for the treatment of patients with severe sepsis (vol 28, pg 48, 2000), CRIT CARE M, 29(2), 2001, pp. 469-469

Authors: Garber, G

Citation: G. Garber, An overview of fungal infections, DRUGS, 61, 2001, pp. 1-12

Authors: Boogaerts, M Winston, DJ Bow, EJ Garber, G Reboli, AC Schwarer, AP Novitzky, N Boehme, A Chwetzoff, E De Beule, K

Citation: M. Boogaerts et al., Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy- A randomized, controlled trial, ANN INT MED, 135(6), 2001, pp. 412-422

Authors: Brooks, JI Gallicano, K Garber, G Angel, JB

Citation: Ji. Brooks et al., Acute monoarthritis complicating therapy with indinavir, AIDS, 14(13), 2000, pp. 2064-2065

Authors: Yamamura, DLR Rotstein, C Nicolle, LE Ioannou, S Johnston, L Schlech, W Thompson, GW Beliveau, C Gourdeau, M Tremblay, CA Bourgault, AM Noel, G St Germain, G Garber, G Evans, G Conly, J Krajden, S Walmsley, S Wang, E Rotstein, C Gregson, D Nicolle, L Williams, K Louie, T Phillips, P

Citation: Dlr. Yamamura et al., Candidemia at selected Canadian sites: Results from the fungal disease registry, 1992-1994, CAN MED A J, 160(4), 1999, pp. 493-499